Scientific Advisory Committee on Oncology Therapies - Membership List

Date: 2009-02-26

Contact Bureau of Policy, Science and International Programs Enquiries

THERAPEUTIC PRODUCTS DIRECTORATE

Membership List

Chair:

Alexander H.G. Paterson, MB, ChB, MD, FRCP, FACP
Chair, Alberta Breast Cancer Program
Professor, Department of Medicine and Oncology, University of Calgary
Medical Oncologist, Department of Medical Oncology, Tom Baker Cancer Centre
Calgary, Alberta

Core Members:

Rick Abbott, BScPharm, RPEBC
Pharmacy Manager, Provincial Systemic Therapy, Cancer Care Program, Dr. H. Bliss Murphy Cancer Centre, Eastern Health
St. John’s, Newfoundland and Labrador

Harley J. Ast, MA, SCM
Patient Advocate
Advisory Member, Saskatchewan Leadership Team of the Campaign to Control Cancer
Regina, Saskatchewan

Charles A. Butts, MD, FRCPC
Medical Oncologist, Division of Medical Oncology, Cross Cancer Institute
Associate Professor, Department of Oncology, University of Alberta
Edmonton, Alberta

Diana Ermel
Patient Advocate
President, Canadian Breast Cancer Network
Regina, Saskatchewan

Kong E. Khoo, MD, FRCPC
Medical Oncologist, British Columbia Cancer Agency, Centre for the Southern Interior
Clinical Assistant Professor, Department of Medical Oncology, University of British Columbia
Kelowna, British Columbia

Kara E. Laing, MD, FRCPC
Clinical Chief, Cancer Care Program, Dr. H. Bliss Murphy Cancer Centre, Eastern Health
Assistant Professor, Department of Medicine, Memorial University
St. John’s, Newfoundland and Labrador

Mark N. Levine, MD, FRCPC
Professor, Department of Oncology, McMaster University
Medical Oncologist, Henderson General Hospital, Hamilton Health Sciences
Hamilton, Ontario

Ronald E. MacCormick, MD, FRCPC
Medical Director, Cape Breton Cancer Centre
Associate Professor, Department of Medicine and Department of Radiation Oncology
Dalhousie University
Halifax, Nova Scotia

Wojciech Morzycki, MD, FRCPC
Medical Oncologist, Division of Medical Oncology, QEII Health Sciences Centre
Assistant Professor, Department of Medicine, Dalhousie University
Halifax, Nova Scotia

Lynne Nakashima, BScPharm, PharmD
Registered Pharmacist
Pharmacy Professional Practice Leader, Bristish Columbia Cancer Agency, Vancouver Cancer Centre
Vancouver, British Columbia

Lesley K. Seymour, MD, FRCPC, PhD
Co-Director, Investigational New Drug Program, National Cancer Institute of Canada, Clinical Trials Group
Professor, Department of Oncology, Queen’s University
Kingston, Ontario

Ian F. Tannock, MD, FRCPC, PhD
Daniel E Bergsagel Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital
Professor, Department of Medical Biophysics, University of Toronto
Toronto, Ontario

Maureen E. Trudeau, MA, MD, FRCPC
Head, Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre
Professor, Department of Medical Oncology, University of Toronto
Toronto, Ontario

Ad Hoc Members:

Allan Donner, PhD
Professor, Department of Epidemiology and Biostatistics, Schulich School of Medicine
University of Western Ontario
London, Ontario

William K. Evans, MD, FRCPC
President, Juravinski Cancer Centre, Hamilton Health Sciences
Professor, Department of Oncology, McMaster University
Hamilton, Ontario

J. Ted Gerstle, MD, FRCSC, FACS, FAAP
Program Director, Division of General Surgery, Hospital for Sick Children
Assistant Professor, Department of Surgery, University of Toronto
Toronto, Ontario 

Wendy R. Parulekar, MD, FRCPC
Physician Coordinator, Investigational New Drug Program, National Cancer Institute of Canada, Clinical Trials Group
Assistant Professor, Department of Oncology, Queen’s University
Kingston, Ontario